On October 6-7, Chordate Medical exhibited its product Ozilia Migraine at a neurology symposium held at the large hospital The Walton Centre in Liverpool. In connection with the event, the company also had the opportunity to provide a separate training on the company’s migraine treatment for nurses and specialist doctors. The group initially intends to use the treatment in their private practice, says the company’s CEO Anders Weilandt in an interview.
Medtech company Chordate Medical has developed a CE-marked nerve-stimulating treatment method that offers a drug-free alternative for chronic migraine. This treatment was previously called Kinetic Oscillation Stimulation (K.O.S.), but is now known under the brand Ozilia Migraine.
Training in Liverpool supports market introduction
Ozilia is currently being introduced in various countries, including the UK, Finland, and Germany. As a step in this launch, Chordate Medical recently visited The Walton Centre, a leading neurology hospital with a catchment area of approximately four million people.
During 6-7 September, The Walton Centre NHS Foundation Trust arranged a neurology symposium in Liverpool, where Chordate Medical gave practical training in its treatment method to seven specialist doctors and nurses. The training was led by the company’s clinical application specialist, Petra Libert.
Opportunities for Chordate Medical
With a staff of approximately 1,450 people, The Walton Centre annually treats over 140,000 patients in neurology, neurosurgery, pain management and rehabilitation. This makes the hospital a central hub for neurological care in the region. Now the medical profession, primarily in private care, intends to introduce Ozilia into its treatment arsenal.
BioStock took the opportunity to ask Chordate Medical’s CEO Anders Weilandt a few questions to find out more about what this means for the company’s marketing efforts.
First of all, how was the training conducted?
– The Ozilia treatment is easy to perform and learn, so the initial focus was on the assessment to see if the patient’s nose is suitable for the treatment and what to look out for before prescribing the treatment. This was followed by a hands-on exercise in carrying out the treatment. Finally, we had some time for questions and discussion.
What is the next step – when can we expect a commercial order from The Walton Centre?
– The clinic, which has already received equipment and materials on trial, is now planning to initially treat 10 patients and evaluate the practical results. After that, we hope that they will move on to regular treatment of those patients who are suitable and who want to switch from drug therapy, or who are suitable for other reasons.
What other initiatives are you taking to strengthen your market launches?
– Right now, we are fully focused on supporting customers who want to get started with practical use in our chosen markets. This applies to all markets that we are present on. Of course, in the beginning, it is a matter of a few clinics in each market. But this is generally how it starts, first with one step and then one step at a time.
– As we have communicated, we are starting on the private clinic side, with a few exceptions. The reason for this is, of course, that there are shorter decision-making paths, and the question of how and who should pay is much easier to deal with.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.